Mar 29, 2023 / 02:00PM GMT
Unidentified Company Representative -
Good morning, and welcome to the ProQR Therapeutics Analyst and Investor R&D event. (Operator Instructions)
At this time, I would like to turn the call over to your host, Sarah Kiely, Vice President of Investor Relations and Corporate Affairs at ProQR Therapeutics. Please go ahead, Sarah.
Sarah Cue Kiely - ProQR Therapeutics N.V. - VP of IR & Corporate Communications
Thank you, and good day, everyone. We appreciate you joining our event today. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Affairs at ProQR . Today's event will take an in-depth look at our Axiomer RNA editing platform technology and our plans to advance it.
On Slide 2, you'll find the agenda for the event and our speakers. From the management team are Daniel de Boer, our Founder and CEO; Gerard Platenburg, our Chief Scientific Officer; and Rene Beukema, our Chief Corporate Development Officer and General Counsel. We're also very pleased to have Dr. Peter Beal of UC Davis, present on ADAR.
Following the
ProQR Therapeutics NV R&D Day Transcript
Mar 29, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers